Iovance Biotherapeutics (NASDAQ: IOVA) stock skyrocketed 31.15% on July 23, 2025, reaching $4.11 after a remarkable 30% surge earlier in the session. The biotech company’s dramatic rise follows significant competitive developments and positive data releases that have sparked intense investor interest and retail trading activity.
FDA Rejection of Rival Drug Boosts IOVA Position
The primary catalyst behind IOVA’s massive surge was the FDA’s complete response letter (CRL) rejection of Replimune’s competing melanoma treatment RP1 on July 22, 2025. The FDA indicated that Replimune’s IGNYTE trial “was not considered an adequate and well-controlled clinical investigation to provide substantial evidence of effectiveness”. This regulatory setback for RP1 eliminates a key competitor to Iovance’s Amtagvi in the advanced melanoma market.
Replimune’s stock plummeted 75% following the FDA rejection, creating a clear competitive advantage for Iovance. With RP1 off the table, Amtagvi now maintains its position as the only FDA-approved tumor-infiltrating lymphocyte (TIL) therapy for solid tumors, strengthening its market dominance.
Strong Clinical Data Fuels Confidence
Iovance recently released impressive real-world data showing Amtagvi achieved a 61% response rate in third-line melanoma patients and a 48.8% overall objective response rate across 41 evaluable patients. The company also announced five-year survival data demonstrating a 20% five-year overall survival rate, unprecedented for any therapy in patients with advanced melanoma previously treated with immune checkpoint inhibitors.
These long-term results validate Amtagvi’s potential as a breakthrough treatment, with the median duration of response reaching 36.5 months and nearly one-third of responders maintaining their response at the five-year mark.
Retail Investor Frenzy and Short Squeeze Dynamics
IOVA has become a target for retail investors seeking short squeeze opportunities, with the stock featuring a significant short interest of 34.5%. A viral Reddit post from an investor with a $408,000 position in IOVA has generated substantial social media buzz, with the poster predicting price targets of $10-$15.
The broader market is experiencing a resurgence of retail-driven speculation, with call option trading hitting 70% of total options trades—the highest since the 2021 meme stock frenzy. Iovance fits the profile of highly shorted biotech stocks that retail investors are targeting for potential squeezes.
Analyst Optimism Despite Volatility
Wall Street analysts maintain bullish sentiment on IOVA, with an average price target of $12.22 representing potential upside of over 200% from current levels. Chardan Capital reaffirms its $25 price target, while HC Wainwright maintains a $20 target despite recent volatility.
The consensus “Buy” rating from 10 analysts reflects confidence in Amtagvi’s commercial potential, with GlobalData projecting peak sales could exceed $1.5 billion in melanoma alone.
IOVA 1-Month Price Chart – July 2025
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
Key Events
What to Watch Next
Key catalysts for IOVA include:
- Upcoming lung cancer clinical data readouts from the IOV-LUN-202 trial
- Second-line melanoma study results
- European regulatory approvals for Amtagvi
- Q2 2025 earnings results scheduled for August 6, 2025
Investors should monitor manufacturing scale-up progress and commercial execution as Iovance works to capitalize on its competitive advantage. The company ended Q1 2025 with $359.7 million in cash, providing financial runway for expansion.
How Picks :
KSS Stock Rockets 100% as Reddit Crowd Targets Kohl’s – Is a Short Squeeze Just Getting Started?
GM Stock shares skid on $1.1 billion tariff hit, wiping out quarterly gains